Login to Your Account



INDIAN DRUGMAKERS SHOULD EXPECT FDA INSPECTIONS

U.S. FDA’s Margaret Hamburg: No bull’s eye on Indian drug developers

By Mari Serebrov
Regulatory Editor

Wednesday, February 26, 2014

A rash of recent inspections that led to FDA enforcement actions against a number of Indian biopharma companies doesn’t mean the U.S. agency is targeting drugmakers in that country.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription